References
Key articles
Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. Clin Infect Dis. 2021 Jan 23;72(1):e1-48.Full text Abstract
Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - Lyme disease. May 2023 [internet publication].Full text
Mead P, Petersen J, Hinckley A. Updated CDC recommendation for serologic diagnosis of lyme disease. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):703.Full text Abstract
Mygland A, Ljøstad U, Fingerle V, et al; European Federation of Neurological Societies. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010 Jan;17(1):8-16;e1-4.Full text Abstract
American Academy of Pediatrics. Lyme disease. In: Kimberlin DW, Brady MT, Jackson MA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018: 515-23.
National Institute for Health and Care Excellence. Lyme disease. Oct 2018 [internet publication].Full text
Reference articles
1. Kullberg BJ, Vrijmoeth HD, van de Schoor F, et al. Lyme borreliosis: diagnosis and management. BMJ. 2020 May 26;369:m1041.Full text Abstract
2. Tibbles CD, Edlow JA. Does this patient have erythema migrans? JAMA. 2007 Jun 20;297(23):2617-27. Abstract
3. Marques AR, Strle F, Wormser GP. Comparison of lyme disease in the United States and Europe. Emerg Infect Dis. 2021 Aug;27(8):2017-24.Full text Abstract
4. Ogrinc K, Lusa L, Lotrič-Furlan S, et al. Course and outcome of early European lyme neuroborreliosis (Bannwarth Syndrome): clinical and laboratory findings. Clin Infect Dis. 2016 Aug 1;63(3):346-53.Full text Abstract
5. Nau R, Christen HJ, Eiffert H. Lyme disease: current state of knowledge. Dtsch Arztebl Int. 2009 Jan;106(5):72-81;quiz 82, I.Full text Abstract
6. Schwartz AM, Hinckley AF, Mead PS, et al. Surveillance for Lyme disease - United States, 2008-2015. MMWR Surveill Summ. 2017 Nov 10;66(22):1-12.Full text Abstract
7. Centers for Disease Control and Prevention. Data and surveillance. Aug 2022 [internet publication].Full text
8. Kugeler KJ, Schwartz AM, Delorey MJ, et al. Estimating the frequency of lyme disease diagnoses, United States, 2010-2018. Emerg Infect Dis. 2021 Feb;27(2):616-19.Full text Abstract
9. World Health Organization. Lyme borreliosis in Europe: influences of climate and climate change epidemiology, ecology and adaptation measures. Sep 2006 [internet publication].Full text
10. Sykes RA, Makiello P. An estimate of Lyme borreliosis incidence in Western Europe†. J Public Health (Oxf). 2017 Mar 1;39(1):74-81.Full text Abstract
11. Burn L, Vyse A, Pilz A, et al. Incidence of lyme borreliosis in Europe: a systematic review (2005-2020). Vector Borne Zoonotic Dis. 2023 Apr;23(4):172-94.Full text Abstract
12. Rosenberg R, Lindsey NP, Fischer M, et al. Vital signs: trends in reported vectorborne disease cases - United States and Territories, 2004-2016. MMWR Morb Mortal Wkly Rep. 2018 May 4;67(17):496-501.Full text Abstract
13. Thomson MC, Stanberry LR. Climate change and vectorborne diseases. N Engl J Med. 2022 Nov 24;387(21):1969-78.Full text Abstract
14. Steere AC, McHugh G, Suarez C, et al. Prospective study of coinfection in patients with erythema migrans. Clin Infect Dis. 2003 Apr 15;36(8):1078-81.Full text Abstract
15. Pritt BS, Mead PS, Johnson DK, et al. Identification of a novel pathogenic Borrelia species causing Lyme borreliosis with unusually high spirochaetaemia: a descriptive study. Lancet Infect Dis. 2016 May;16(5):556-64.Full text Abstract
16. Wormser GP. A brief history of OspA vaccines including their impact on diagnostic testing for Lyme disease. Diagn Microbiol Infect Dis. 2022 Jan;102(1):115572.Full text Abstract
17. McVicar M, Rivera I, Reyes JB, et al. Ecology of ixodes pacificus ticks and associated pathogens in the Western United States. Pathogens. 2022 Jan 13;11(1).Full text Abstract
18. Singh SK, Girschick HJ. Lyme borreliosis: from infection to autoimmunity. Clin Microbiol Infect. 2004;10:598-614. Abstract
19. Steere AC, Coburn J, Glickstein L. The emergence of Lyme disease. J Clin Invest. 2004 Apr;113(8):1093-101.Full text Abstract
20. Halsey SJ, Allan BF, Miller JR. The role of Ixodes scapularis, Borrelia burgdorferi and wildlife hosts in lyme disease prevalence: a quantitative review. Ticks Tick Borne Dis. 2018 Jul;9(5):1103-14.Full text Abstract
21. Oliver JD, Bennett SW, Beati L, et al. Range expansion and increasing Borrelia burgdorferi infection of the tick ixodes scapularis (acari: ixodidae) in Iowa, 1990-2013. J Med Entomol. 2017 Nov 7;54(6):1727-34.Full text Abstract
22. Hayes EB, Piesman J. How can we prevent Lyme disease? N Engl J Med. 2003 Jun 12;348(24):2424-30. Abstract
23. Daltroy LH, Phillips C, Lew R, et al. A controlled trial of a novel primary prevention program for Lyme disease and other tick-borne illnesses. Health Educ Behav. 2007 Jun;34(3):531-42. Abstract
24. Bratton RL, Whiteside JW, Hovan MJ, et al. Diagnosis and treatment of Lyme disease. Mayo Clin Proc. 2008 May;83(5):566-71.Full text Abstract
25. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. Clin Infect Dis. 2021 Jan 23;72(1):e1-48.Full text Abstract
27. Dessau RB, van Dam AP, Fingerle V, et al. To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis: a position paper of ESGBOR, the ESCMID study group for Lyme borreliosis. Clin Microbiol Infect. 2018 Feb;24(2):118-24.Full text Abstract
28. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - Lyme disease. May 2023 [internet publication].Full text
29. Centers for Disease Control and Prevention. Lyme disease-signs and symptoms of untreated lyme disease. Jan 2021 [internet publication].Full text
30. Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep. 1995 Aug 11;44(31):590-1.Full text Abstract
31. Mead P, Petersen J, Hinckley A. Updated CDC recommendation for serologic diagnosis of lyme disease. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):703.Full text Abstract
32. Mygland A, Ljøstad U, Fingerle V, et al; European Federation of Neurological Societies. EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. 2010 Jan;17(1):8-16;e1-4.Full text Abstract
33. Moore A, Nelson C, Molins C, et al. Current guidelines, common clinical pitfalls, and future directions for laboratory diagnosis of Lyme disease, United States. Emerg Infect Dis. 2016 Jul;22(7):1169–77.Full text Abstract
34. Branda JA, Steere AC. Laboratory diagnosis of Lyme borreliosis. Clin Microbiol Rev. 2021 Jan 27 [Epub ahead of print]. Abstract
35. Aguero-Rosenfeld ME, Wang G, Schwartz I, et al. Diagnosis of Lyme borreliosis. Clin Microbiol Rev. 2005 Jul;18(3):484-509.Full text Abstract
36. Government of Canada. Lyme disease. October 2019 [internet publication].Full text
37. Huppertz HI, Bartmann P, Heininger U, et al. Rational diagnostic strategies for Lyme borreliosis in children and adolescents: recommendations by the Committee for Infectious Diseases and Vaccinations of the German Academy for Pediatrics and Adolescent Health. Eur J Pediatr. 2012 Nov;171(11):1619-24.Full text Abstract
38. American Academy of Pediatrics. Lyme disease. In: Kimberlin DW, Brady MT, Jackson MA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018: 515-23.
39. American Academy of Pediatrics. Tetracyclines. In: Kimberlin DW, Brady MT, Jackson MA, eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018: 905-6.
40. Steere AC, Malawista SE, Newman JH, et al. Antibiotic therapy in Lyme disease. Ann Intern Med. 1980 Jul;93(1):1-8. Abstract
41. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of early manifestations of Lyme disease. Ann Intern Med. 1983 Jul;99(1):22-6. Abstract
42. Massarotti EM, Luger SW, Rahn DW, et al. Treatment of early Lyme disease. Am J Med. 1992 Apr;92(4):396-403. Abstract
43. Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med. 1992 Aug 15;117(4):273-80. Abstract
44. Luger SW, Paparone P, Wormser GP, et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob Agents Chemother. 1995 Mar;39(3):661-7.Full text Abstract
45. Nowakowski J, Nadelman RB, Forseter G, et al. Doxycycline versus tetracycline therapy for Lyme disease associated with erythema migrans. J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):223-7. Abstract
46. Eppes SC, Childs JA. Comparative study of cefuroxime axetil versus amoxicillin in children with early Lyme disease. Pediatrics. 2002 Jun;109(6):1173-7. Abstract
47. Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003 May 6;138(9):697-704. Abstract
48. National Institute for Health and Care Excellence. Lyme disease. Oct 2018 [internet publication].Full text
49. Stupica D, Collinet-Adler S, Blagus R, et al. Treatment of erythema migrans with doxycycline for 7 days versus 14 days in Slovenia: a randomised open-label non-inferiority trial. Lancet Infect Dis. 2023 Mar;23(3):371-79.Full text Abstract
50. Luft BJ, Dattwyler RJ, Johnson RC, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med. 1996 May 1;124(9):785-91.Full text Abstract
51. Berende A, Ter Hofstede HJM, Vos FJ, et al. Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis. Neurology. 2019 Mar 26;92(13):e1447-55.Full text Abstract
52. Waddell LA, Greig J, Lindsay LR, et al. A systematic review on the impact of gestational Lyme disease in humans on the fetus and newborn. PLoS One. 2018 Nov 12;13(11):e0207067.Full text Abstract
53. Nadelman RB, Nowakowski J, Fish D, et al; Tick Bite Study Group. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med. 2001 Jul 12;345(2):79-84.Full text Abstract
54. Steere AC, Levin RE, Molloy PJ, et al. Treatment of Lyme arthritis. Arthritis Rheum. 1994 Jun;37(6):878-88. Abstract
55. Eckman MH, Steere AC, Kalish RA, et al. Cost effectiveness of oral as compared with intravenous antibiotic treatment for patients with early Lyme disease or Lyme arthritis. N Engl J Med. 1997 Jul 31;337(5):357-63.Full text Abstract
56. Cameron DJ, Johnson LB, Maloney EL. Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease. Expert Rev Anti Infect Ther. 2014 Sep;12(9):1103-35.Full text Abstract
57. Torbahn G, Hofmann H, Rücker G, et al. Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: a network meta-analysis. JAMA Dermatol. 2018 Nov 1;154(11):1292-303.Full text Abstract
58. Cardenas-de la Garza JA, De la Cruz-Valadez E, Ocampo-Candiani J, et al. Clinical spectrum of Lyme disease. Eur J Clin Microbiol Infect Dis. 2019 Feb;38(2):201-8.Full text Abstract
59. Nemeth J, Bernasconi E, Heininger U, et al. Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Med Wkly. 2016 Dec 5;146:w14353.Full text Abstract
60. Eliassen KE, Hjetland R, Reiso H, et al. Symptom load and general function among patients with erythema migrans: a prospective study with a 1-year follow-up after antibiotic treatment in Norwegian general practice. Scand J Prim Health Care. 2017 Mar;35(1):75-83.Full text Abstract
61. Berende A, ter Hofstede HJ, Vos FJ, et al. Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med. 2016;374:1209-1220.Full text Abstract
62. Aucott JN. Posttreatment Lyme disease syndrome. Infect Dis Clin North Am. 2015 Jun;29(2):309-23.Full text Abstract
63. Mead P. Epidemiology of lyme disease. Infect Dis Clin North Am. 2022 Sep;36(3):495-521.Full text Abstract
64. Steere AC, Glickstein L. Elucidation of Lyme arthritis. Nat Rev Immunol. 2004 Feb;4(2):143-52.Full text Abstract
65. Koedel U, Fingerle V, Pfister HW. Lyme neuroborreliosis-epidemiology, diagnosis and management. Nat Rev Neurol. 2015 Aug;11(8):446-56.Full text Abstract
66. Asbrink E, Hovmark A, Olsson I. Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients. Zentralbl Bakteriol Mikrobiol Hyg A. 1986 Dec;263(1-2):253-61.Full text Abstract
67. Dattwyler RJ, Halperin JJ, Volkman DJ, et al. Treatment of late Lyme borreliosis - randomized comparison of ceftriaxone and penicillin. Lancet. 1988 May 28;1(8596):1191-4. Abstract
68. Dattwyler RJ, Wormser GP, Rush TJ, et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien Klin Wochenschr. 2005 Jun;117(11-12):393-7. Abstract
69. Scheffold N, Herkommer B, Kandolf R, et al. Lyme carditis--diagnosis, treatment and prognosis. Dtsch Arztebl Int. 2015 Mar 20;112(12):202-8.Full text Abstract
Use of this content is subject to our disclaimer